المؤلفون: A. Yakovlev V., S. Shilov N., E. Berezikova N., N. Yakovleva F., A. Teplyakov T., E. Grakova V., K. Kopeva V., I. Efremov A., А. Яковлев В., С. Шилов Н., Е. Березикова Н., Н. Яковлева Ф., А. Тепляков Т., Е. Гракова В., К. Копьева В., И. Ефремов А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 3 (2021); 444-449 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 3 (2021); 444-449 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: heart failure, arterial hypertension, obstructive sleep apnea, valsartan/sacubitril, CPAP therapy, сердечная недостаточность, артериальная гипертензия, обструктивное апноэ сна, валсартан/сакубитрил, СИПАП-терапия

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2502/2183; van Deursen VM, Urso R, Laroche C, et al. Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16:103-11. DOI:10.1002/ejhf.30.; Lindberg E, Gislason T. Epidemiology of sleep-related obstructive breathing. Sleep Med Rev. 2000;4:321-7. DOI:10.1053/smrv.2000.0118.; Mentz RJ, Fiuzat M. Sleep-Disordered Breathing in Patients with Heart Failure Heart Failure Clin. 2014;10:243-50. DOI:10.1016/j.hfc.2013.10.001.; Butt M, Dwivedi G, Khair O, et al. Obstructive sleep apnea and cardiovascular disease. Int J Cardiol. 2010;139:7-16. DOI:10.1016/j.ijcard.2009.05.021.; Marin JM, Agusti A, Villar I, et al. Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension. JAMA. 2012;307(20):2169-76. DOI:10.1001/jama.2012.3418.; Bitter T, Westerheide N, Prinz C, et al. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J. 2011;32:61-74. DOI:10.1093/eurheartj/ehq327.; Nieto FJ, Young TB, Lind BК, et al. Association of sleep-disordered breathing, sleep apnea and hypertension in a large community-based study. JAMA. 2000;283(14):1829-36. DOI:10.1001/jama.283.14.1829.; Sauer AJ, Cole R, Jensen BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24(2):167-76. DOI:10.1007/s10741-018-9757-1.; Khder Y, Shi V, McMurray JJV, et al. Sacubitril/Valsartan (LCZ696) in Heart Failure. Handb Exp Pharmacol. 2017;243:133-65. DOI:10.1007/164_2016_77.; Denker MG, Cohen DL. Use of continuous positive airway pressure for sleep apnea in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2014;23(5):462-67. DOI:10.1097/MNH.0000000000000047.; Mansukhani MP, Vungarala S, Somers VK. Cardiovascular Benefits of Continuous Positive Airway Pressure: The Quest Continues. Ann Am Thorac Soc. 2020;17(4):427-28. DOI:10.1513AnnalsATS.202001-026ED.; Carmo J, Araújo I, Marques F, et al. Sleep-disordered breathing in heart failure: The state of the art after the SERVE-HF trial. Rev Port Cardiol. 2017;36(11):859-67. DOI:10.1016/j.repc.2017.06.007.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации ОССНРКО-РНМОТ. сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. DOI:10.18087/cardio.2475.; Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. DOI:10.5664/jcsm.6506.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7. DOI:10.1164/ajrccm.166.1.at1102.; Javaheri S, Caref EB, Chen E, et al. Sleep apnea testing and outcomes in a large cohort of medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med. 2011;183:539-46. DOI:10.1164/rccm.201003-0406OC.; Liu Y, Huang Z, Huang K, et al. The Clinical Value of N-Terminal Pro B-Type Natriuretic Peptide in Evaluating Obstructive Sleep Apnea in Patients With Coronary Artery Disease. J Clin Sleep Med. 2019;15(10):1403-9. DOI:10.5664/jcsm.7962.; Hübner RH, Mokhtari NE, Freitag S, et al. NT-proBNP is not elevated in patients with obstructive sleep apnoea. Respir Med. 2008;102(1):134-42. DOI:10.1016/j.rmed.2007.07.023.; Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57(2):119-27. DOI:10.1016/j.jacc.2010.08.627.; Tugcu A, Guzel D, Yildirimturk O, et al. Evaluation of right ventricular systolic and diastolic function in patients with newly diagnosed obstructive sleep apnea syndrome without hypertension. Cardiology. 2009;113:184-92. DOI:10.1159/000193146.; Tasci S, Manka R, Scholtyssek S, et al. NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. Clin Res Cardiol. 2006;95(1):23-30. DOI:10.1007/s00392-006-0315-9.; Nakamura S, Asai K, Kubota Y, et al. Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleepdisordered breathing: a meta-analysis. Clin Res Cardiol. 2015;104:208-16. DOI:10.1007/s00392-014-0774-3.; Arias MA, García-Río F, Alonso-Fernández A, et al. Pulmonary hypertension in obstructive sleep apnoea: Effects of continuous positive airway pressure: A randomized, controlled cross-over study. Eur Heart J. 2006;27:1106-13. DOI:10.1093/eurheartj/ehi807.; https://www.rpcardio.com/jour/article/view/2502

الاتاحة: https://www.rpcardio.com/jour/article/view/2502
https://doi.org/10.20996/1819-6446-2021-06-07

المؤلفون: S. Shilov N., E. Berezikova N., A. Popova A., E. Samsonova N., A. Teplyakov T., E. Grakova V., K. Kopeva V., A. Molokov V., I. Yakovleva V., С. Шилов Н., Е. Березикова Н., А. Попова А., Е. Самсонова Н., А. Тепляков Т., Е. Гракова В., К. Копьева В., А. Молоков В., И. Яковлева В.

المصدر: Meditsinskiy sovet = Medical Council; № 7 (2021); 78-86 ; Медицинский Совет; № 7 (2021); 78-86 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ischemic heart disease, diabetes mellitus, osteoporosis, bisphosphonates, alendronate, ишемическая болезнь сердца, сахарный диабет, остеопороз, бисфосфонаты, алендронат

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6143/5593; von der Recke P., Hansen M.A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106(3):273-278. doi:10.1016/s0002-9343(99)00028-5.; Laroche M., Pecourneau V., Blain H., Breuil V., Chapurlat R., Cortet B. et al. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84(4):427-432. doi:10.1016/j.jbspin.2016.09.022.; Sprini D., Rini G.B., Stefano L.D., Cianferotti L., Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117-119. Available at: https://pubmed.ncbi.nlm.nih.gov/25285139/.; Шилов С.Н., Тепляков А.Т., Яковлева И.В., Попова А.А., Березикова Е.Н., Гракова Е.В. Клиническая и патогенетическая взаимосвязь хронической сердечной недостаточности, сахарного диабета 2 типа и остеопороза. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):6-13. doi:10.17802/2306-1278-2018-7-1-6-13.; Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-1809. doi:10.1056/NEJMoa074941.; Beaupre L.A., Morrish D.W., Hanley D.A., Maksymowych W.P., Bell N.R., Juby A.G., Majumdar S.R. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22(3):983-991. doi:10.1007/s00198-010-1411-2.; Sambrook P.N., Cameron I.D., Chen J.S., March L.M., Simpson J.M., Cumming R.G., Seibel M.J. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int. 2011;22(9):2551-2556. doi:10.1007/s00198-010-1444-6.; Santos L.L., Cavalcanti T.B., Bandeira F.A. Vascular effects of bisphosphonates - a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47-54. doi:10.4137/CMED.S10007.; Асланян Н.С., Бланкова З.Н., Виценя М.В., Михайлов Г.В., Кулев Б.Д., Агеев Ф.Т. Взаимосвязь артериального кальциноза и остеопороза. Влияние терапии бисфосфонатами на сосудистую стенку. Сердце: журнал для практикующих врачей. 2016;15(3):151—160. doi:10.18087/rhj.2016.3.2215.; Kawahara T., Nishikawa M., Kawahara C., Inazu T., Sakai K., Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327-2335. doi:10.1161/CIRCULATIONAHA.113.001534.; Kranenburg G., Bartstra J.W., Weijmans M., de Jong P.A., Mali W.P., Verhaar H.J. et al. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis. 2016;252:106-115. doi:10.1016/j.atherosclerosis.2016.06.039.; Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. doi:10.1056/NEJMoa067312.; Pittman C.B., Davis L.A., Zeringue A.L., Caplan L., Wehmeier K.R., Scherrer J.F. et al. Myocardial infarction risk among patients with fractures receiving bisphosphonates. Mayo Clin Proc. 2014;89(1):43-51. doi:10.1016/j.mayocp.2013.08.021.; Herrera L., Leal I., Lapi F., Schuemie M., Arcoraci V., Cipriani F. et al. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. Osteoporos Int. 2015;26(5):1499-1506. doi:10.1007/s00198-014-3020-y.; Grosso A., Douglas I., Hingorani A., MacAllister R., Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE. 2009;4(3):e4720. doi:10.1371/journal.pone.0004720.; Vestergaard P., Schwartz K., Pinholt E.M., Rejnmark L., Mosekilde L. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int. 2010;86(5):335-342. doi:10.1007/s00223-010-9349-0.; Kang J.H., Keller J.J., Lin H.C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013;24(1):271-277. doi:10.1007/s00198-012-2213-5.; Hartle J.E., Tang X., Kirchner H.L., Bucaloiu I.D., Sartorius J.A., Pogrebnaya Z.V. et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am J Kidney Dis. 2012;59(5):636-644. doi:10.1053/j.ajkd.2011.11.037.; Huang W.F., Tsai Y.W., Wen Y.W., Hsiao F.Y., Kuo K.N., Tsai C.R. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause. 2010;17(1):57-63. doi:10.1097/gme.0b013e3181b34749.; Reid I.R., Horne A.M., Mihov B., Stewart A., Garratt E., Wong S. et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379(25):2407-2416. doi:10.1056/NEJMoa1808082.; Wolfe F., Bolster M.B., O'Connor C.M., Michaud K., Lyles K.W., Colon-Emeric C.S. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28(5):984-991. doi:10.1002/jbmr.1792.; Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009;265(5):581-592. doi:10.1111/j.1365-2796.2008.02065.x.; Sharma A., Einstein A.J., Vallakati A., Arbab-Zadeh A., Walker M.D., Mukherjee D. et al. Risk of atrial fibrillation with use of oraland intravenous bisphosphonates. Am J Cardiol. 2014;113(11):1815-1821. doi:10.1016/j.amjcard.2014.03.008.; Kim D.H., Rogers J.R., Fulchino L.A., Kim C.A., Solomon D.H., Kim S.C. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS ONE. 2015;10(4):e0122646. doi:10.1371/journal.pone.0122646.; Kirchmayer U., Sorge C., Sultana J., Lapi F., Onder G., Agabiti N. et al. Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy. Ther Adv Drug Saf. 2019;10:2042098619838138. doi:10.1177/2042098619838138.; Kemeny-Suss N., Kasneci A., Rivas D., Afilalo J., Komarova S.V., Chalifour L.E., Duque G. Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vasc Pharmacol. 2009;51(5-6):350-358. doi:10.1016/j.vph.2009.09.002.; Bondo L., Eiken P., Abrahamsen B. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients - a nationwide register-based open cohort study. Osteoporos Int. 2013;24(1):245-252. doi:10.1007/s00198-012-2024-8.; Cummings S.R., Lui L.Y., Eastell R., Allen I.E. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med. 2019;179(11):1491-1500. doi:10.1001/jamainternmed.2019.2779.; Colon-Emeric C.S., Mesenbrink P., Lyles K.W., Pieper C.F., Boonen S., Delmas P. et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25(1):91-97. doi:10.1359/jbmr.090704.; Bliuc D., Tran T., van Geel T., Adachi J.D., Berger C., van den Bergh J. et al. Reduced bone loss is associated with reduced mortality risk in subjects exposed to nitrogen bisphosphonates: a mediation analysis. J Bone Miner Res. 2019;34(11):2001-2011. doi:10.1002/jbmr.3816.; Kanazawa I., Yamaguchi T., Hayashi K., Takase H., Shimizu T., Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010;339(6):519-524. doi:10.1097/MAJ.0b013e3181db6dfe.; D'Ascenzo F., Agostoni P., Abbate A., Castagno D., Lipinski M.J., Vetrovec G.W. et al. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178-185. doi:10.1016/j.atherosclerosis.2012.10.065.; Reid I.R., Horne A.M., Mihov B., Stewart A., Garratt E., Wong S. et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;79(25):2407-2416. doi:10.1056/NEJMoa1808082.; Varela I., Pereira S., Ugalde A.P., Navarro C.L., Suarez M.F., Cau P. et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008;14(7):767-772. doi:10.1038/nm1786.; Марченкова Л.А., Древаль А.В., Прохорова Е.А., Лосева В.А. Приверженность больных постменопаузальным остеопорозом комбинированной терапии алендронатом натрия и колекальциферолом и ее влияние на эффективность лечения. Проблемы эндокринологии. 2014;(4):22-29. doi:10.14341/probl201460422-29.; Cooper A., Drake J., Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60(8):896-905. doi:10.1111/j.1742-1241.2006.01059.x.; https://www.med-sovet.pro/jour/article/view/6143

الاتاحة: https://www.med-sovet.pro/jour/article/view/6143
https://doi.org/10.21518/2079-701X-2021-7-78-86